Cellepus Therapeutics

Cellepus Therapeutics is a biotechnology company developing allogeneic CAR-T cell therapies specifically engineered to treat solid tumors. The company utilizes a proprietary gamma-delta 1/3 (γδ1/3) T-cell platform, which is designed to enhance tumor homing and innate cytotoxic activity compared to circulating γδ2 cells. A core component of their technology is a novel Zeta-less CAR signaling architecture, which aims to improve therapeutic durability by reducing T-cell exhaustion and avoiding suppression cascades commonly associated with traditional CD28/4-1BB frameworks. Their manufacturing process leverages cord blood donors to create off-the-shelf, scalable therapies, and they are also pursuing tumor-specific antigen discovery programs to increase precision and limit off-tumor effects.

These advancements are intended to address the significant challenges in treating solid tumors, where traditional T-cell therapies have historically struggled with penetration, persistence, and exhaustion. By focusing on precision-guided, turbocharged γδ1/3 cells, Cellepus aims to provide a more effective, off-the-shelf therapeutic option for patients. The company was founded by experts in tumor immunology, including Dr. Jose Conejo-Garcia and Dr. Scott Antonia, who bring extensive experience in identifying T-cell responses in cancer patients and developing successful immunotherapies for lung and ovarian cancers. Their approach seeks to overcome current clinical impasses in solid tumor treatment through a differentiated, state-of-the-art cell therapy platform.